FTM, the pancreatic trial MOS improvement with Bavi, is as PPHM wrote in their PR: "modest". I observe that, if the survival profile is something like what Geo suggested, Bavi is bringing benefits by bringing forward more longer term survivors. If not, I would be inclined to say that the improved ORR (doubled) is lacking if the overall survival didn't show meaningful improvement. PPHM hasn't released the KM plot or other info that illustrates how well patients did for overall survival, but one might presume that when they can, they will. As of now, apparently they can't. We must again wait to receive clear information, when PPHM presents the trial results at an upcoming conference. I am guessing that, if PPHM has pancreatic cancer Bavi trial OS results worth trumpeting, they would have done so in this PR. The matter has been left unaddressed by PPHM, for now.
Best wishes and IMO.
KT
News 
Market Data 
Discover 
